{"id":506,"date":"2022-03-24T13:46:25","date_gmt":"2022-03-24T17:46:25","guid":{"rendered":"https:\/\/research.ncsu.edu\/administration\/?page_id=506"},"modified":"2026-02-20T21:08:43","modified_gmt":"2026-02-21T02:08:43","slug":"application-review-process","status":"publish","type":"page","link":"https:\/\/research.ncsu.edu\/administration\/compliance\/research-compliance\/irb\/application-review-process\/","title":{"rendered":"Step 3: Application Review Process"},"content":{"rendered":"\n\n\n\n\n
Once submitted, your research proposal will be reviewed by IRB administrators and, if needed later in the process, board members and expert consultants. To avoid delays, researchers are expected to provide a fully complete application where all required documents are attached and the details remain consistent across all materials.<\/p>\n\n\n\n
Once you submit your application, the IRB staff performs an initial check called “pre-review.” Pre-review is only done after the application is submitted to the IRB office, not before. During this step, IRB staff will:<\/p>\n\n\n\n
Please Note:<\/strong> It is completely normal for the IRB to return an application for revisions once or twice at this stafe. Researchers may be asked to provide more detail, upload missing materials, or align documents with regulatory requirements or recent changes. Prolonged revision cycles are usually a result of researchers ignoring or not fully incorporating the IRB’s provided feedback. Reviewing and thoroughly addressing all IRB feedback before resubmitting a protocol application is expected if you wish for your application to move forward.<\/p>\n\n\n\n Protocol applications move to final review once the pre-review process is complete and the application has been submitted to the IRB office in a condition that it is ready for final review. The final review process and associated timeline greatly depend on the level of IRB review required, the risk involved in the study, and what policies, regulations, and standards the study is subject to.<\/p>\n\n\n\n Once the application is ready for final review, IRB staff will either:<\/p>\n\n\n\n After the final review, the IRB will either approve your study or, more commonly, return it with a list of required changes (often called “stipulations”). This is where many researchers get tripped up and experience delays in their IRB approval process. <\/p>\n\n\n\n To get your study approved as quickly as possible, avoid these common mistakes:<\/p>\n\n\n\n Before clicking resubmit, do a final side-by-side comparison of the stipulations provided to you with your revised application and supporting documentation to ensure every single point has been addressed.<\/p>\n\n\n\n Researchers should utilize the following IRB webpages to prepare for the IRB review process and for guidance on how to draft application materials.<\/p>\n\n\n\n The review timeframes provided are only for planning purposes and are not guaranteed deadlines. Please note that the review “clock” begins only when a fully complete application\u2014including all required supplemental documents\u2014is ready for final review. This is usually not when an application is first submitted to the IRB office.<\/p>\n\n\n\n Protocol approval will likely take longer (or, occasionally, happen sooner) based on a few key factors:<\/p>\n\n\n\n The estimated timelines above do not apply to student projects. Because student research requires a highly collaborative, iterative process, IRB approval typically takes much longer. If you are a student, please be aware of the following:<\/p>\n\n\n\n Depending on your study’s design, funding, or technology, your protocol may require additional reviews. These reviews usually occur during the IRB pre-review process; a few occur after IRB approval. All of these reviews ensure your study meets specific legal, regulatory, or safety standards.<\/p>\n\n\n \n \n\n Federally funded studies are classified as clinical trials (under 45 CFR 46.102(b)<\/a> if they prospectively assign human participants to an intervention to evaluate biomedical or behavioral health-related outcomes.<\/p>\n\n\n\n \n \n\n Cooperative research involves collaborating with outside people, groups, or organizations. For a detailed discussion, please go to our Cooperative Research webpage<\/a>, but the summary is:<\/p>\n\n\n\n If NC State is the IRB of Record<\/strong> <\/p>\n\n\n\n When collaborating with other institutions and NC State is taking the lead on IRB review, two concurrent reviews are required during the standard IRB process<\/p>\n\n\n\n <\/p>\n\n\n\n If Another Institution is the IRB of Record<\/strong><\/p>\n\n\n\n If an external institution’s IRB is the IRB of Record, NC State researchers must file a request with the NC State IRB for either a:<\/p>\n\n\n\n <\/p>\n\n\n\n If Collaborating with Individual Investigators<\/strong><\/p>\n\n\n\n If your research team includes independent researchers or individuals who are not affiliated with an institution that has its own IRB (with an FWA number) who will be assisting you on your research study, they must be officially covered by NC State’s IRB. <\/p>\n\n\n\n \n \n\n If your study involves specific technologies or sensitive data, you will need NC State University OIT clearance.<\/p>\n\n\n\n \n \n\n Studies funded by the Department of Defense or utilizing DoD personnel\/resources have additional mandatory oversight controls. <\/p>\n\n\n\n \n \n\n If you are studying unique or international populations, an independent subject matter expert may need to evaluate the cultural or legal risks to participants before the IRB conducts the final review of the study.<\/p>\n\n\n\n <\/p>\n\n\n <\/p>\n <\/details>\n\n\n \n \n\n If your study will involve the use of a medical device, ancillary reviews, processes, and regulatory requirements can apply. Please note that if you will be studying a health-related outcome and prospectively assigning participants to an intervention, your study will also be subject to clinical trial regulations.<\/p>\n\n\n\n Investigational Device Exemptions (IDEs)<\/strong><\/p>\n\n\n\n The U.S. Food and Drug Administration categorizes medical devices by risk which dictates whether you need their direct review and approval for your study.<\/p>\n\n\n\n IRB Review<\/strong><\/p>\n\n\n\n The level of IRB review depends directly on the FDA medical device risk category: significant risk or non-significant risk. <\/p>\n\n\n\n Clinical Trials<\/strong><\/p>\n\n\n\n Regardless of the medical device’s risk level or IRB approval path, a medical device study is a clinical trial if research participants will be prospectively assigned to an intervention to evaluate a health-related outcome. <\/p>\n\n\n\n If your study is a clinical trial:<\/strong><\/p>\n\n\n\n Technology<\/strong> and Security Clearances<\/strong><\/p>\n\n\n\n If your study uses a modified or purpose-built (custom) device, you may need additional University review and clearances before the NC State IRB will approve your study. <\/p>\n\n\n\n Those clearances could be from:<\/p>\n\n\n\n Relevant Links and Resources<\/strong><\/p>\n\n\n\nFinal Review<\/h2>\n\n\n\n
\n
Addressing Final Review Feedback<\/h2>\n\n\n\n
\n
\n
Estimated Review Timeframe<\/h2>\n\n\n\n
What Affects Approval Timeline?<\/h3>\n\n\n\n
\n
Average Approval Processing Times<\/strong><\/h3>\n\n\n\n
\n
Important Note for Student Researchers <\/h3>\n\n\n\n
\n
Additional (Ancillary) Reviews<\/h2>\n\n\n\n
\n \n <\/span>\n <\/span>\n
Clinical Trials<\/h2>\n <\/summary>\n
\n
\n \n <\/span>\n <\/span>\n
Cooperative Research <\/h2>\n <\/summary>\n
\n
\n
\n
\n \n <\/span>\n <\/span>\n
Data Management<\/h2>\n <\/summary>\n
\n
\n \n <\/span>\n <\/span>\n
Department of Defense (DoD) Affiliated Research<\/h2>\n <\/summary>\n
\n
\n \n <\/span>\n <\/span>\n
Local and Participant Context Reviews<\/h2>\n <\/summary>\n
\n
\n \n <\/span>\n <\/span>\n
Medical Device Studies<\/h2>\n <\/summary>\n
\n
\n
\n
\n
\n
\n
\n
\n
IRB Lifecycle<\/h3>\n \n